More on influenza vaccine in young children.

摘要: n engl j med 366;26 nejm.org june 28, 2012 2528 formed of the available treatments for multiple sclerosis. They were also reminded and their right to leave study during trial if a relapse or progression disability was diagnosed, they required sign second consent form at this time. Because we instituted these measures, which reviewed approved by every ethics committee competent health authority involved in study, are confident that patients fully aware currently treatment options. Furthermore, it should be considered many needle-phobic tended reject injection therapies, only first-line therapies time began. Approximately 38% laquinimod group 40% those placebo had received sclerosis before began, consented participation.